Calcitriol in cancer treatment: From the lab to the clinic

Molecular Cancer Therapeutics

Volumn 3, Issue 3, 2004, Pages 373-381

  Beer, Tomasz M ^a   Myrthue, Anne ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CALCIPOTRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CARBOPLATIN; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DN 101; DOCETAXEL; DOXERCALCIFEROL; HYDROXYUREA; ISOTRETINOIN; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; TAMOXIFEN; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOTHESIS; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TUMOR MODEL;

ANIMALS; APOPTOSIS; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CELL DIFFERENTIATION; CELL DIVISION; CLINICAL TRIALS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 4444282905     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (150)

1. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr, 2003;89:552-72.
2. Guyton KZ, Kensler TW, Posner GH. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev, 2003;61:227-38.
3. Johnson CS, Hershberger PA, Bernardi RJ, McGuire TF, Trump DL. Vitamin D receptor: a potential target for intervention. Urology, 2002; 60:123-30; discussion 130-21.
4. Zehnder D, Bland R, Hughes SV, et al. Analysis of the tissue distribution of 1α-hydroxylase identifies novel extra-renal sites for the synthesis of 1,25-dihydroxyvitamin D3. Riverside, CA: University of California; 2000. p. 159-62.
5. Lehmann B, Pietzsch J, Kampf A, Meurer M. Human keratinocyte line HaCaT metabolizes 1α-hydroxyvitamin D3 and vitamin D3 to 1α,25-dihydroxyvitamin D3 (calcitriol). J Dermatol Sci, 1998; 18:118-27.
6. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell, 1995;83:835-9.
7. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab, 1988;67:607-13.
8. Holick MF. Vitamin D: a millenium perspective. J Cell Biochem, 2003; 88:296-307.
9. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature, 1992;355:446-9.
10. Christakos S, Barletta F, Huening M, Dhawan P, Liu Y, Porta A, et al. Vitamin D target proteins: function and regulation. J Cell Biochem, 2003; 88:238-44.
11. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol, 2002;147:197-213.
12. Seoane S, Alonso M, Segura C, Perez-Fernandez R. Localization of a negative vitamin D response sequence in the human growth hormone gene. Biochem Biophys Res Commun, 2002;292:250-5.
13. Kitazawa R, Kitazawa S. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun, 2002;290:650-5.
14. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev, 1996; 10: 142-53.
15. Maestro B, Davila N, Carranza MC, Calle C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol, 2003;84:223-30.
16. Zierold C, Darwish HM, DeLuca HF. Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. Proc Natl Acad Sci USA, 1994;91:900-2.
17. Jiang F, Li P, Fornace AJ Jr., Nicosia SV, Bai W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem, 2003;278: 48030-40.
18. Hakim I, Bar-Shavit Z. Modulation of TNF-α expression in bone marrow macrophages: involvement of vitamin D response element. J Cell Biochem, 2003;88:986-98.
19. Thompson PD, Jurutka PW, Whitfield GK, et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun, 2002; 299:730-8.
20. Bikle DD, Ng D, Oda Y, Hanley K, Feingold K, Xie Z. The vitamin D response element of the involucrin gene mediates its regulation by 1,25-dihydroxyvitamin D3. J Invest Dermatol, 2002;119:1109-13.
21. de Boland AR, Morelli S, Boland R. 1,25(OH)2-vitamin D3 signal transduction in chick myoblasts involves phosphatidylcholine hydrolysis. J Biol Chem, 1994;269:8675-9.
22. de Boland AR, Facchinetti MM, Balogh G, Massheimer V, Boland RL. Age-associated decrease in inositol 1,4,5-trisphosphate and diacylglycerol generation by 1,25(OH)2-vitamin D3 in rat intestine. Cell Signal, 1996; 8:153-7.
23. Beno DW, Brady LM, Bissonnette M, Davis BH. Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction. J Biol Chem, 1995;270:3642-7.
24. Gniadecki R. Activation of Raf-mitogen-activated protein kinase signaling pathway by 1,25-dihydroxyvitamin D3 in normal human keratinocytes. J Invest Dermatol, 1996;106:1212-7.
25. Park WH, Seol JG, Kim ES, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCl-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol, 2000;109:576-83.
26. Vazquez G, Boland R, de Boland AR. Modulation by 1,25(OH) 2-vitamin D3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts. Biochim Biophys Acta, 1995;1269:91-7.
27. Bellido T, Morelli S, Fernandez LM, Boland R. Evidence for the participation of protein kinase C and 3′,5′-cyclic AMP-dependent protein kinase in the stimulation of muscle cell proliferation by 1,25-dihydroxyvitamin D3. Mol Cell Endocrinol, 1993; 90:231-8.
28. Santillan GE, Boland RL. Studies suggesting the participation of protein kinase A in 1,25(OH)2-vitamin D3-dependent protein phosphorylation in cardiac muscle. J Mol Cell Cardiol, 1998;30:225-33.
29. Bektas M, Orfanos CE, Geilen CC. Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol Biol (Noisy-le-grand), 2000;46:111-9.
30. de Boland AR, Norman AW. Influx of extracellular calcium mediates 1,25-dihydroxyvitamin D3-dependent transcaltachia (the rapid stimulation of duodenal Ca2+ transport). Endocrinology, 1990;127: 2475-80.
31. Abe E, Miyaura C, Sakagami H. Differentiation of rat myc leukemia cells induced by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA, 1981;78:4990-4.
32. Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol, 2001;165:253-8.
33. Colston KW, Chander SK, Mackay AG, Coombes RC. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol, 1992;44:693-702.
34. Cross HS, Huber C, Peterlik M. Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): influence of extracellular calcium. Biochem Biophys Res Commun, 1991;179:57-62.
35. Yabushita H, Hirata M, Noguchi M, Nakanishi M. Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res, 1996;22:529-39.
36. Nagakura K, Abe E, Suda T, Hayakawa M, Nakamura H, Tazaki H. Inhibitory effect of 1α,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Int, 1986;29:834-40.
37. Fujioka T, Hasegawa M, Ishikura K, Matsushita Y, Sato M, Tanji S. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol, 1998;160:247-51.
38. Higashimoto Y, Ohata M, Nishio K, et al. 1α,25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res, 1996;16:2653-9.
39. Zugmaier G, Jager R, Grage B, Gottardis MM, Havemann K, Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer, 1996;73:1341-6.
40. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology, 1993;132:1952-60.
41. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res, 1994;54:805-10.
42. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res, 1994;14:1077-81.
43. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology, 1995;136:20-6.
44. Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1α ,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol, 1996;58:277-88.
45. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol, 1997;126:83-90.
46. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology, 1997;50:999-1006.
47. Shabahang M, Buffan AE, Nolla JM, et al. The effect of 1,25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor. Ann Surg Oncol, 1996;3:144-9.
48. Tokuumi Y. Correlation between the concentration of 1,25α dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3. Nippon Seikei Geka Gakkai Zasshi, 1995;69:181-90.
49. Hara K, Kusuzaki K, Takeshita H, et al. Oral administration of 1α hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model. Anticancer Res, 2001;21:321-4.
50. Veenstra TD, Londowski JM, Windebank AJ, Brimijoin S, Kumar R. Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. Brain Res Dev Brain Res, 1997;99:53-60.
51. Celli A, Treves C, Stio M. Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation. Neurochem Int, 1999;34:117-24.
52. Naveilhan P, Berger F, Haddad K, et al. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors? J Neurosci Res, 1994;37:271-7.
53. Colston K, Colston MJ, Feldman D. 1,25-Dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology, 1981;108:1083-6.
54. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res, 1999;59:2644-9.
55. McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem, 2001;276:26365-73.
56. Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res, 1996;56:264-7.
57. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev, 1996;10:142-53.
58. Sheikh MS, Rochefort H, Garcia M. Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene, 1995;11:1899-905.
59. Zhuang SH, Burnstein KL. Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology, 1998;139:1197-207.
60. Campbell MJ, Koeffler HP. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst, 1997;89:182-5.
61. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res, 2001;7:1043-51.
62. Reitsma PH, Rothberg PG, Astrin SM, et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature, 1983;306:492-4.
63. Matsumoto K, Hashimoto K, Nishida Y, Hashiro M, Yoshikawa K. Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun, 1990;166:916-23.
64. Kobayashi T, Hashimoto K, Yoshikawa K. Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun, 1993; 196:487-93.
65. Fan FS, Yu WC. 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest, 1995;13:280-6.
66. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J. Inhibitory effects of 1α,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol, 2001;15:1370-80.
67. Hager G, Formanek M, Gedlicka C, Thurnher D, Knerer B, Kornfehl J. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol, 2001;121:103-9.
68. Yen A, Varvayanis S. Late dephosphorylation of the RB protein in G2 during the process of induced cell differentiation. Exp Cell Res, 1994; 214:250-7.
69. Tong WM, Kallay E, Hofer H, et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur J Cancer, 1998;34:2119-25.
70. Haugen JD, Pittelkow MR, Zinsmeister AR, Kumar R. 1α,25-Dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor β2 release. Biochem Biophys Res Commun, 1996;229:618-23.
71. Wu Y, Haugen JD, Zinsmeister AR, Kumar R. 1α,25-Dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells. Biochem Biophys Res Commun, 1997;239:734-9.
72. Vink-van Wijngaarden T, Pols HA, Buurman CJ, Birkenhager JC, van Leeuwen JP. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Eur J Cancer, 1996;32A:842-8.
73. Drivdahl RH, Loop SM, Andress DL, Ostenson RC. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate, 1995;26:72-9.
74. Scharla SH, Strong DD, Subburaman M, Baylink DJ, Linkhart TA. 1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. Endocrinology, 1991;129:3139-46.
75. Elstner E, Linker-Israeli M, Said J, et al. 20-Epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res, 1995;55:2822-30.
76. Studzinski GP, Rathod B, Wang QM, Rao J, Zhang F. Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants. Exp Cell Res, 1997;232:376-87.
77. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol, 1996;58:367-76.
78. Sergeev IN, Rhoton WB, Norman AW. 1,25-Dihydroxyvitamin D3, intracellular Ca2 + and apoptosis in breast cancer cell lines. In: BR Norman AW, Thomasset M, editors. Vitamin D. Chemistry, biology and clinical applications of the steroid hormone. Riverside, CA: University of California; 1997. p. 473-4.
79. Vandewalle B, Wattez N, Lefebvre J. Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett, 1995;97: 99-106.
80. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1α,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther, 2002;1: 667-77.
81. Elstner E, Linker-Israeli M, Umiel T, et al. Combination of potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res, 1996;56:3570-6.
82. Modzelewski RA, Hershberger PA, Johnson CS, Trump DL. Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumors in vitro. Proc AACR, 1999;40:580.
83. Pepper C, Thomas A, Hoy T, Milligan D, Bentley P, Fegan C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood, 2003;101:2454-60.
84. James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol, 1996;58:395-401.
85. Wagner N, Wagner KD, Schley G, Badiali L, Theres H, Scholz H. 1,25-Dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Exp Eye Res, 2003; 77:1-9.
86. Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol, 2003; 84:181-92.
87. Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res, 1999;59: 4848-56.
88. Polek TC, Stewart LV, Ryu EJ, Cohen MB, Allegretto EA, Weigel NL. p53 is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology, 2003;144:50-60.
89. Xie SP, James SY, Colston KW. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol, 1997;154:495-504.
90. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1α,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res, 2001;7: 4164-73.
91. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1α,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology, 2002;143:2508-14.
92. Rocker D, Ravid A, Liberman UA, Garach-Jehoshua O, Koren R. 1,25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol Cell Endocrinol, 1994;106:157-62.
93. Sergeev IN, Rhoten WB. Regulation of intracellular calcium in human breast cancer cells. Endocrine, 1998;9:321-7.
94. Koren R, Rubenstein E, Gamady A, et al. 1,25-Dihydroxyvitamin D3 inhibits the activation of C-JUN N-terminal kinase by physiological and environmental stresses in keratinocytes. In: BR Norman AW, Thomasset M, editors. Vitamin D endocrine system, structural, biological, genetic and clinical aspects. Riverside, CA: University of California; 2000. p. 621-2.
95. Lee J, Youn JI. The photoprotective effect of 1,25-dihydroxyvitamin D3 on ultraviolet light B-induced damage in keratinocyte and its mechanism of action. J Dermatol Sci, 1998;18:11-8.
96. Hansen CM, Frandsen TL, Brunner N, Binderup L. 1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis, 1994;12:195-202.
97. Young MR, Ihm J, Lozano Y, Wright MA, Prechel MM. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother, 1995;41:37-45.
98. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. a,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers & Prev, 1997;6: 727-32.
99. Sung V, Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol, 2000; 164:133-43.
100. Yudoh K, Matsuno H, Kimura T. 1α,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med, 1999; 133:120-8.
101. Koli K, Keski-Oja J. 1α,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth & Differ, 2000;11:221-9.
102. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol, 1997;19:15-27.
103. Gonzalez-Sancho JM, Alvarez-Dolado M, Munoz A. 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett, 1998;426:225-8.
104. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1α,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res, 2000;87:214-20.
105. Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Invest Dermatol Symp Proc, 1996;1:97-101.
106. Yu WD, McElwain MC, Modzelewski RA, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst, 1998;90:134-41.
107. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol, 2001;28:49-55.
108. Moffatt KA, Johannes WU, Miller GJ. 1α,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res, 1999;5:695-703.
109. Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol, 2002; 168:756-61.
110. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res, 1997; 57:3759-64.
111. Wieder R, Wang Q, Uytingco M, et al. 1,25-Dihydroxyvitamin D3 and all-trans retinoic acid promote apoptosis and sensitize breast cancer cells to the effects of chemotherapeutic agents. Proc Am Soc Clin Oncol, 1998;17:107a.
112. Sundaram S, Chaudhry M, Reardon D, Gupta M, Gewirtz DA. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat, 2000;63:1-10.
113. Torres R, Calle C, Aller P, Mata F. Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells. Mol Cell Biochem, 2000;208:157-62.
114. Koga M, Sutherland RL. Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antiestrogen to inhibit T-47D human breast cancer cell proliferation. J Steroid Biochem Mol Biol, 1991;39:455-60.
115. Guzey M, Sattler C, DeLuca HF. Combinational effects of vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines. Biochem Biophys Res Commun, 1998;249:735-44.
116. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett, 1993;75:35-9.
117. Anzano MA, Smith JM, Uskokovic MR, et al. 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res, 1994;54:1653-6.
118. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol, 1994;72:537-45.
119. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res, 1993;53:2534-7.
120. Hsiao M, Tse V, Carmel J, et al. Functional expression of human p21 (WAF1/CIP1) gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity. Biochem Biophys Res Commun, 1997;233: 329-35.
121. Dunlap N, Schwartz GG, Eads D, et al. 1α,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1α,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer, 2003;89:746-53.
122. Polar MK, Gennings C, Park M, Gupta MS, Gewirtz DA. Effect of the vitamin D3 analog ILX 23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts. Cancer Chemother Pharmacol, 2003;51:415-21.
123. Peehl DM, Seto E, Feldman D. Rationale for combination ketoconazole/vitamin D treatment of prostate cancer. Urology, 2001;58:123-6.
124. Peehl DM, Seto E, Hsu JY, Feldman D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol, 2002;168:1583-8.
125. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of oral 1,25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urol Oncol, 1995;1:195-8.
126. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol, 1998;159:2035-9; discussion 2039-40.
127. Koeffler HP, Hirji K, Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep, 1985;69:1399-407.
128. Rustin GJ, Quinnell TG, Johnson J, Clarke H, Nelstrop AE, Bollag W. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer, 1996;74:1479-81.
129. Petrini M, Caracciolo F, Corini M, Valentini P, Sabbatini AR, Grassi B. Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study. Haematologica, 1991;76:200-3.
130. Slapak CA, Desforges JF, Fogaren T, Miller KB. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol, 1992;41:178-83.
131. Hellstrom E, Robert KH, Samuelsson J, et al. Treatment of myelodysplastic syndromes with retinoic acid and 1α -hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol, 1990;45:255-61.
132. Papapoulos SE, Clemens TL, Sandler LM, et al. The effect of renal function on changes in circulating concentrations of 1,25-dihydroxycholecalciferol after an oral dose. Clin Sci, 1982;62:427-9.
133. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res, 1999;5:1339-45.
134. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer, 2001;91:2431-9.
135. Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer, 2003;97:1217-24.
136. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther, 2002;72:648-59.
137. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol, 1999;26:14-18.
138. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol, 1999;26:19-23.
139. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol, 2001;12:1273-9.
140. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol, 2001;28:8-15.
141. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol, 2003;21:123-8.
142. Finlay IG, Stewart GJ, Ahkter J, Morris DL. A phase one study of the hepatic arterial administration of 1,25-dihydroxyvitamin D3 for liver cancers. J Gastroenterol Hepatol, 2001;16:333-7.
143. Morris DL, Jourdan JL, Finlay I, Gruenberger T, The MP, Pourgholami MH. Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: pilot study in patients with hepatocellular carcinoma. Int J Oncol, 2002;21:901-6.
144. Kissmeyer AM, Binderup E, Binderup L, et al. Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol, 1997; 53:1087-97.
145. Bouillon R, Verstuyf A, Verlinden L, et al. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol, 1995;50: 577-83.
146. Bouiloon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev, 1995;16:200-57.
147. Bower M, Colston KW, Stein RC, et al. Topical calcipotriol treatment in advanced breast cancer. Lancet, 1991;337:701-2.
148. Liu G, Oettel K, Ripple G, et al. Phase I trial of 1α-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res, 2002;8:2820-7.
149. Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer, 1998;78: 6-13.
150. Evans TR, Colston KW, Lofts FJ, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer, 2002;86:680-5.